{"id":616,"date":"2020-10-31T07:05:47","date_gmt":"2020-10-31T07:05:47","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=616"},"modified":"2020-10-31T07:05:47","modified_gmt":"2020-10-31T07:05:47","slug":"28-oct-2020-tocilizumab-early-administration-associated-with-decreased-mortality-in-critically-ill-patients","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/28-oct-2020-tocilizumab-early-administration-associated-with-decreased-mortality-in-critically-ill-patients\/","title":{"rendered":"(28 Oct 2020) Tocilizumab- early administration associated with decreased mortality in critically ill patients"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Early Tocilizumab Dosing is Associated with Improved Survival In Critically Ill Patients Infected With Sars-CoV-2<\/p>\n<p class=\"\">https:\/\/www.medrxiv.org\/content\/10.1101\/2020.10.27.20211433v1.full.pdf<\/p>\n<p class=\"\">This was a multi-center study of patients infected with SARS-CoV-2, admitted between 3\/13\/20 and 4\/16\/20, requiring mechanical ventilation. Parameters that were evaluated included age, sex, race, usage of steroids, inflammatory markers, and comorbidities. Early dosing was defined as a tocilizumab dose administered prior to or within one (1) day of intubation. Late dosing was defined as a dose administered greater than one (1) day after intubation. A control group that was treated only with standard of care, and without tocilizumab, was utilized for comparison (untreated). Findings We studied 118 patients who required mechanical ventilation. Eighty-one (81) received tocilizumab, compared to 37 who were untreated. Early tocilizumab therapy was associated with a statistically significant decrease in mortality as compared to patients who were untreated (p=0.003). Dosing tocilizumab late was associated with an increased mortality compared to the untreated group (p=0.006). Interpretation Early tocilizumab administration was associated with decreased mortality in critically ill SARS-Co-V-2 patients, but a potential detriment was suggested by dosing later in a patient&#8217;s course.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Early Tocilizumab Dosing is Associated with Improved Survival In Critically Ill Patients Infected With Sars-CoV-2 https:\/\/www.medrxiv.org\/content\/10.1101\/2020.10.27.20211433v1.full.pdf This was a multi-center study of patients infected with SARS-CoV-2, admitted between 3\/13\/20 and 4\/16\/20, requiring mechanical ventilation. Parameters that were evaluated included age,&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/28-oct-2020-tocilizumab-early-administration-associated-with-decreased-mortality-in-critically-ill-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(28 Oct 2020) Tocilizumab- early administration associated with decreased mortality in critically ill patients&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/616"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=616"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/616\/revisions"}],"predecessor-version":[{"id":617,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/616\/revisions\/617"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}